ArticleSpinal cord2016
Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury.
J Wöllner et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
23 papers cite it
this paperpooled itcites it